Abstract
The efficacy and toxicity of combined paclitaxel and gemcitabine was evaluated in 54 chemotherapy-naive patients with metastatic non-small cell lung cancer (NSCLC). Gemcitabine i.v. 1000 mg/m2 was administered on days 1 and 8 and paclitaxel 200 mg/m2 as a continuous 3-hour infusion on day 1. Treatment was repeated every 21 days. Patients had a median age of 53 years. ECOG performance status was 0 or 1 in 48 patients. 41 patients (75.9%) had initial stage IV disease; histology was mainly adenocarcinoma (46.3%). 2 patients (4.3%) achieved a complete response and 15 (31.9%) achieved a partial response giving an overall response rate of 36.2% (95% CI: 22.4–49.9%); 19 patients (40.4%) had stable disease and 10 (21.3%) had progressive disease. The median survival time was 51 weeks (95% CI: 46.5–59.3), with a 1-year survival probability of 0.48 (95% CI: 0.34–0.63). Grade 3/4 neutropenia and febrile neutropenia occurred in 15.2% and 2.2% of courses, respectively. Grade 3/4 thrombocytopenia was rare (1.8% of courses). Peripheral neurotoxicity developed in 25 patients (47.2%), mostly grade 1/2. Arthalgia/myalgia was observed in 30 patients (56.6%), generally grade 1 or 2. Grade 3 abnormal levels of serum glutamate pyruvate transaminase (SGPT) and serum glutamate oxaloacetate transaminase (SGOT) occurred in 5 patients (9.4%) and 1 patient (1.9%), respectively. Combined paclitaxel and gemcitabine is an active and well-tolerated regimen for the treatment of advanced NSCLC, and warrants further investigation in comparative, randomized trials. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abratt RP, Bezwoda WR, Goedhals L and Hacking DJ (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15: 744–749
Alberola V, Rosell R, Gonzalez-Larriba J-L, Molina F, Ayala F, Garcia-Conde J, Benito D and Perez JM (1995) Single-agent Taxol, 3-hour infusion in untreated advanced non-small lung cancer. Ann Oncol 6: 49–52
Anderson H, Lund B, Bach F, Thatcher N, Walling J and Hansen HH (1994) Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 12: 1821–1826
Chang A, Kim K, Glick T, Anderson T, Karp D and Johnson D (1993) Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 85: 388–394
Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronata P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C and Tonato M (1997) Cisplatin-gemcitabine combination in advanced non-small cell lung cancer (NSCLC). A phase II study. J Clin Oncol 15: 297–303
Depierre A, Chastang C, Quoix E, Lebeau A, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D and Clavier J (1994) Vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomised trial. Ann Oncol 5: 37–42
Frasci G, Panza N, Comella P, Nicolella GP, Natale M, Manzione L, Bilancia D, Cioffi R, Maiorino L, De Cataldis G, Belli M, Micillo E, Mascia V, Massidda B, Lorusso V, De Lena M, Carpagnano F, Contu A, Pusceddu G and Comella G (1999) Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: A phase I-II study. J Clin Oncol 17: 2316–2325
Fukuoka M, Takada M, Yokoyama A, Kurita Y and Niitani H (1997) Phase II studies of gemcitabine for non-small cell lung cancer in Japan. Semin Oncol 24: S7–42–S7–46
Gatzemeier U, Heckmayer M, Neuhauss R, Schluter I, Pawel JV, Wagner H and Dreps A (1995) Phase II study with paclitaxel for the treatment of advanced inoperable NSCLC. Lung Cancer 12: 101–106
Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M and Voi M (1996) Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter extended phase II study. Eur J Cancer 32: 243–248
Georgoulias V, Kouroussis C, Androulakis N, Kakolyris S, Dimopoulos MA, Papadakis E, Bouros D, Apostolopoulou F, Papadimitriou C, Agelidou A, Hatzakis K, Kalbakis K, Kotsakis A, Vardakis N and Vlachonicolis J (1999) Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. J Clin Oncol 17: 914–920
Giaccone G, Smit E, Laan D, Splinter T, van Meerbeek J and Postmus P (1998a) Phase I/II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer. Proc Am soc Clin Oncol 17: 486a (abstr 1869)
Giaccone G, Splinter TAW, Debruyne C, Kho GS, Lianes P, van Zandwijk N, Pennucci MC, Scagliotti G, van Meerbeeck J, van Hoesel Q, Curran D, Sahmoud T and Postmus PE for the European Organization for Research Treatment of Cancer Lung Cancer Cooperative Group (1998b) Randomized study of paclitaxel-cisplatin versus teniposide-cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 16: 2133–2141
Hainsworth JD, Urba WJ, Hon JK, Thompson KA, Stagg MP, Hopkins LG, Thomas M and Greco FA (1998) One-hour paclitaxel plus carboplatin in the treatment of advanced non-small-cell lung cancer: results of a multicentre, phase II trial. Eur J Cancer 34: 654–658
Hainsworth JD, Burris HA, Erland JB, Morrissey LH, Meluch AA, Kalman LA, Hon JK, Scullin DC, Smith SW and Greco FA (1999) Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung cancer. Cancer 85: 1269–1276
Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M and De Vore RF (1996) Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial. J Clin Oncol 14: 2054–2060
Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Klastersky J and Sculier JP (1995) Dose finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. European Lung Cancer Working Party. Lung Cancer 12: 117–125
Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus PE, Pinedo HM and Peters GJ (1999) Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with non-small cell lung cancer. J Clin Oncol 17: 2190–2197
Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S and Ozols RF (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response and survival analysis. J Clin Oncol 13: 1860–1870
Lilenbaum RC and Green MR (1993) Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11: 1391–1402
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Minna JD, Higgins GA and Glatstein EJ (1984) Cancer of the lung. In Cancer: Principles and Practice of Oncology, DeVita V, Hellman S, Roxenburg S. 536. Lippincott: Philadelphia
Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111: 1710–1717
Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff IH and Hong WK (1993) Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85: 384–388
Noble S and Goa KL (1997) Gemcitabine A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54: 447–472
Peters GJ and Ackland SP (1996) New antimetabolites in preclinical and clinical development. Exp Opin Investig Drugs 5: 637–679
Pirker R, Krajnik G, Zochbauer S, Malayeri R, Kneussl M and Huber H (1995) Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC). Ann Oncol 6: 833–835
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R and Gandhi V (1995) Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22: 3–10
Poole CJ, Perren T, Hogberg T, Cook J, Jenkins AH, Ridderheim M and Anderson K (1997) Phase I study to investigate alternate sequencing of the combination of gemcitabine and paclitaxel in ovarian carcinoma. Eur J Cancer 33: S121 (abstr 543)
Rowinsky EK and Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332: 1004–1014
Sandler A, Raghavan D, Meropol N, Meyers T, Kindler H, Fox S, Perez R and Einhorn LH (1997) A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors. Eur J Cancer 33: S248 (abstr 1120)
Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C and Einhorn LH (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18: 122–130
Schiff PB, Fant J and Horwitz SB (1979) Promotion of microtubule assembly in vitro by paclitaxel. Nature 277: 665–667
Schiller JH, Harrington D, Sandler A, Belani C, Langer C, Krook J and Johnson DH Eastern Cooperative Oncology Group (2000) A randomised phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 19: 2 (abstr)
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10: 1–10
Sørensen JB, Stenbygaard LE, Dombernowsky P and Hansen HH (1999) Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell, lung cancer. Ann Oncol 10: 1043–1049
Wiseman LR and Spencer CM (1998) Paclitaxel An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs & Aging 12: 305–334
Yokoyama A, Nakai Y, Yoneda S, Kurita Y and Niitani H (1997) Activity of gemcitabine in the treatment of patients with non-small cell lung cancer. A multicenter phase II study. Anticancer Drugs 8: 574–581
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Douillard, J., Lerouge, D., Monnier, A. et al. Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. Br J Cancer 84, 1179–1184 (2001). https://doi.org/10.1054/bjoc.2001.1784
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1784
Keywords
This article is cited by
-
Progress in systemic therapy for advanced-stage urothelial carcinoma
Nature Reviews Clinical Oncology (2024)
-
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors
Investigational New Drugs (2012)
-
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype
Cancer Chemotherapy and Pharmacology (2011)
-
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
British Journal of Cancer (2008)
-
Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy
Cancer Chemotherapy and Pharmacology (2007)
